Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Taiwan Biotech Touts Drug Derived From Chinese Medicine To Treat Cancer Patients

This article was originally published in PharmAsia News

Executive Summary

Taiwan’s Maywufa Bio Pharmaceutical Group launched a cancer-related fatigue treatment derived from an herb used in traditional Chinese medicine and plans to investigate it for cardiovascular use with clinical trials in the United States.

You may also be interested in...

Taiwan Announces $1.9 Billion Mega Fund To Nurture Biotech Industry

HONG KONG - Taiwan's push to do with the biotech sector what it did with IT two decades ago will be anchored on a $1.9 billion "mega fund" unveiled earlier this month

Questions Circle INDs; Industry Needs Guidance For Probiotics, Say Experts

FDA should consider issuing a guidance for probiotics similar to the 2004 industry guidance for botanical drugs, panelists said at a recent Drug Information Association conference

Taiwan, Japan Eye Drug Regulation Streamlining To Curb Costs

Regulators from Japan and Taiwan met in late December to review prospects for convergence and pointed to manufacturing and new drug approvals as areas that were ripe for harmonization agreements.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts